News from adventrx pharmaceuticals, inc

Mar 11, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"

 ADVENTRX Pharmaceuticals, Inc. today completed its previously announced corporate name change to "Mast Therapeutics, Inc."  In addition,...

Feb 28, 2013, 17:15 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be "Mast Therapeutics,...

Feb 28, 2013, 16:01 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced its plans to develop ANX-188 in complications of arterial disease, initially as...

Feb 26, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reviewed the platform of data and know-how that supports development of ANX-188 in...

Feb 25, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at...

Feb 11, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of...

Feb 05, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present...

Jan 30, 2013, 07:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated patient recruitment in its pivotal phase 3 clinical...

Jan 04, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Appointment of Chief Financial Officer

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the appointment of Brandi L. Roberts to Chief Financial Officer and Senior Vice...

Jan 02, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX To Present At The 6th Annual OneMedForum Emerging Company Finance Conference On January 8

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at...

Dec 19, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX To Initiate Phase 3 Study Of ANX-188

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that ANX-188 drug product for use in the phase 3 clinical study of ANX-188...

Dec 03, 2012, 08:30 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Launch Of New Corporate Website

 ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the launch of its redesigned and updated corporate website,www.adventrx.com....

Nov 05, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Reports Third Quarter 2012 Financial Results

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended September 30, 2012. "With a strong cash...

Oct 25, 2012, 16:05 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today provided details regarding the phase 3 clinical study of ANX-188 (purified poloxamer 188) in...

Oct 23, 2012, 08:30 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Conference Call To Review Protocol For Phase 3 Clinical Study Of ANX-188

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it will hold a conference call at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific...

Oct 02, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Engages Theradex Systems, Inc. to Manage Phase 3 Clinical Study of ANX-188

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has engaged Theradex® Systems, Inc., a contract research organization...

Sep 07, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Ted W. Love, M.D., has joined its Board of Directors. Dr. Love most recently...

Aug 28, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Aug 14, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Announces Appointment Of Chief Medical Officer

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical...

Aug 06, 2012, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

ADVENTRX Reports Second Quarter 2012 Financial Results

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended June 30, 2012. "We start the second...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer